P. Mrozek-Gorska

The paper uses PDX models to show KLF4 re-expression reduces B-ALL leukemia load and sensitizes tumors to chemotherapy, suggesting Azacitidine could regulate KLF4 as a therapeutic option.

This study identifies EBNA2 as essential for early EBV infection of naive B-cells, showing it drives activation, proliferation, and prevents cell death, while other latent genes have minimal or no effect during the pre-latent phase.

This study shows that EBV lytic reactivation causes global chromatin remodeling and transcriptome disruption in host cells before viral DNA replication.

This study shows EBV rapidly reprograms primary human B-lymphocytes transcriptionally within 24 hours of infection, leading to metabolic changes and cell cycle entry by day three.

This study identifies BZLF1's role in reactivating Epstein-Barr virus by interacting with the chromatin remodeler INO80 to overcome epigenetic silencing.